Skip to main content

Summary

for people ages 18–70 (full criteria)
at San Francisco, California
study started
estimated completion:

Description

Summary

The investigators believe that glucagon therapy will have a positive impact on key parameters of colonoscopy such as cecal intubation time, withdrawal time, total procedure time, adenoma detection rate, endoscopist's assessment of the difficulty of the procedure, patient comfort, and patient's willingness to undergo a repeat colonoscopy.

Official Title

Role of Glucagon in Outpatient Colonoscopy? A Prospective Double-Blind Randomized Controlled Trial

Details

Glucagon transiently decreases peristalsis of smooth muscle in the gastrointestinal tract. It is widely used by radiologists to improve diagnostic yields of upper and lower GI barium contrast examinations. Glucagon is also routinely administered intravenously for all endoscopic retrograde cholangiopancreatography (ERCP) throughout the United States to facilitate canulation of the duodenal papilla and sphincterotomy. Glucagon has been used at the dose of 1-3 mg intravenously by Dr. John Cello in over 5000 ERCP examinations. The role of glucagon in facilitating colonoscopy remains controversial however and is not considered "routine". Several studies have evaluated the effect of glucagon on colonoscopy with varying results. No large scale randomized controlled trial has been performed to conclusively establish the effect of routine glucagon administration prior to colonoscopy. The investigators plan to carry out a randomized double blind, placebo controlled trial that studies key parameters of a colonoscopy such as cecal intubation time, withdrawal time, total procedure time, adenoma detection rate, endoscopist's assessment of the difficulty of the procedure, patient comfort, and patient's willingness to undergo a repeat colonoscopy.

Keywords

Colon Cancer glucagon, screening colonoscopy Glucagon Glucagon-Like Peptide 1

Eligibility

You can join if…

Open to people ages 18–70

  • Any subject who has already been already cleared for and scheduled to undergo colonoscopy at SFGH endoscopy center.

You CAN'T join if...

  1. Refusal to give informed consent.
  2. Age <18 or >70.
  3. Prior intra-abdominal surgery
  4. Diabetes
  5. Pheochromocytoma
  6. Insulinoma
  7. Liver disease (Child-Pugh Score >6)
  8. Pregnancy

Location

  • San Francisco General Hospital accepting new patients
    San Francisco, California, 94117, United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT02078726
Phase
Phase 4
Lead Scientist
Anupam Aditi
Study Type
Interventional
Last Updated
January 2016
I’m interested in this study!